Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Glioblastoma 10Breast Neoplasms 10Neoplasms 9Leukemia, Myeloid, Acute 9Neoplasm Metastasis 7Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 6Carcinoma, Hepatocellular 6Prostatic Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Pancreatic Neoplasms 5Myelodysplastic Syndromes 5Lung Neoplasms 5Hematologic Neoplasms 5Ovarian Neoplasms 4Multiple Myeloma 4Glioma 4Uterine Cervical Neoplasms 3Sarcoma 3Melanoma 3Head and Neck Neoplasms 3Carcinoma, Renal Cell 3Astrocytoma 3Triple Negative Breast Neoplasms 2Solid Tumors 2Solid Tumor 2Recurrence 2Rectal Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Osteosarcoma 2

Interventions

Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Advance Solid Tumors × 90 days × Clear all
NCT07529535 2026-04-17

A First-in-Human Study of ALK-N001 for Injection in Patients With Advanced Solid Tumors

Zhejiang Anglikang Pharmaceutical Co., Ltd.

Phase 1 Suspended
16 enrolled
Other solid neoplasm

Advance Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡